https://www.selleckchem.com/pr....oducts/deferoxamine-
The overall and cause-specific survival was 96% and 86% at 3 and 5 years. No late complications related to brachytherapy were described. Conclusion A HDR-BT boost is useful to decrease the incidence of local recurrence of NPC to 5%. With a fractionated schedule of 3-4 fractions in two days, Rotterdam applicator and 3-D planning, no late complications are described. Therefore we recommend to use brachytherapy boost in all early NPC.Aim This study aimed to commission the Elekta Infinity™ working in 6 and 10 MV photon beam in
Like
Comment
Share
